By Nqobile Dludla JOHANNESBURG, March 4 (Reuters) - Aspen Pharmacare aims to secure sub‑Saharan African approval for Eli Lilly's blockbuster weight‑loss drug Mounjaro ‌as early as this year, its CEO said on Wednesday, capitalising ‌on soaring regional demand for obesity treatments. South Africa-based Aspen’s push to register Mounjaro across the ​region signals its bid to become a key manufacturing and distribution partner for global drugmakers eyeing one of the last major untapped markets for GLP‑1 weigh ...